We demonstrate that the endothelial-specific cotargeting of both NRP receptors, NRP1 and NRP2, provides effective inhibition against tumor growth and secondary site metastasis in multiple cancer models, likely by potentiating the rapid delivery of VEGFR-2 to late-endosomes for degradation. Here, NRP1 is linked to neoplasm.